Development of a mortality score to assess risk of adverse drug reactions among hospitalized patients with moderate to severe chronic kidney disease

Table 2 Odd Ratio and Goodness of Fit for Sequential Models of Mortality Predictions of ADR events

Variable	Models
Variable	1 Comorbidities	2 Comorbidities + Type of Medication	3 Comorbidities + Type of Medication + Lab Results	4 Comorbidities + Type of Medication + Lab Results + Total Medication Use	5 Comorbidities + Type of Medication + Lab Results + Total Medication Use + Renal Replacement Therapy
^a Heart Disease	0.44 (0.18–1.08)	0.44 (0.17–1.15)	0.43 (0.16–1.15)	0.42 (0.15–1.19)	0.46 (0.16–1.32)
Dyslipidaemia	0.32 (0.13–0.84)	0.25 (0.09–0.70)	0.21 (0.07–0.64)	0.24 (0.08–0.73)	0.23 (0.07–0.71)
^b Electrolyte Disorder	3.56 (1.19–10.70)	6.36 (1.92–21.08)	5.79 (1.70–19.77)	5.31 (1.49–18.88)	5.72 (1.57–20.89)
^c Psychotic Agents		9.42 (3.04–29.12)	8.78 (2.68–28.81)	6.13 (1.77–21.26)	6.02 (1.76–20.64)
Creatinine Kinase ≥171 U/L			6.72 (1.70–26.52)	7.68 (1.75–33.66)	6.81 (1.49–31.20)
≥ 23 No. medications				4.27 (1.49–12.24)	4.66 (1.58–13.79)
Conservative management					1.59 (0.55–4.66)
Hosmer and Lemeshow Test	0.418	0.860	0.623	0.899	0.643
Nagelkerke R Square	0.127	0.267	0.329	0.393	0.399
p value	0.005	< 0.001	< 0.001	< 0.001	< 0.001

Abbreviation: GFR, glomerular filtration rate
Data are presented as odd ratios (95% confidence interval) unless otherwise stated
^aHeart Disease is defined as presence of vascular or/and heart failure aetiology
^bElectrolyte Disorder is defined as presence of hypokalaemia or hyperkalaemia
^cPsychrotic Agents is defined as drugs that are classified as psychotropic drugs
^dSI conversion: To convert Creatinine kinase to μkat/L, multiply by 58.82

ISSN: 2050-6511